<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911028-0046</DOCNO><DOCID>911028-0046.</DOCID><HL>   Technology Brief -- SmithKline Beecham PLC:   Warning on Intradermal Use   Given on Engerix-B Vaccine</HL><DATE>10/28/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B4</SO><CO>   SBE</CO><MS>CONSUMER NON-CYCLICAL (NCY)</MS><IN>DRUG MANUFACTURERS (DRG)</IN><RE>EUROPE (EU)GREAT BRITAIN (UK)WESTERN EUROPE (WEU)</RE><LP>   SmithKline Beecham PLC warned that intradermaladministration of its hepatitis B vaccine, Engerix-B, reducesits effectiveness.   The drug is intended to prevent infection with hepatitisB. Intradermal means under the skin.</LP><TEXT>   The Philadelphia pharmaceutical company cited a recentreport concerning intradermal use of the drug for firefighters, police officers and nurses in four communities.Many of those vaccinated intradermally requiredre-vaccination, said the report, prepared by the U.S. Centersfor Disease Control.   Engerix-B requires intramuscular administration to beproperly effective, a company spokesman said. Clinicalstudies have shown that intramuscular administration is moreeffective than intradermal administration, he said. Moreover,intradermal vaccination, which must be applied directlybeneath the top layer of the skin, is technically much harderto perform, he added.</TEXT></DOC>